Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Can Coronavirus Disease 2019 (Covid-19) Trigger Exacerbation of Multiple Sclerosis? a Retrospective Study Publisher Pubmed



Barzegar M1, 2 ; Vaheb S2, 3 ; Mirmosayyeb O1, 2 ; Afsharisafavi A2, 4 ; Nehzat N2 ; Shaygannejad V1, 2
Authors

Source: Multiple Sclerosis and Related Disorders Published:2021


Abstract

The effect of coronavirus disease (COVID-19) on the risk of relapse in multiple sclerosis (MS) have been unknown. In this retrospective study of 41 relapsing-remitting MS patients, number of relapses in pre-defined at risk-period (ARP) was compared with the previous two years. During the previous two years, a total of 32 attacks was reported, which 5 (15.6%) were during the at-risk period. After adjusting for age and sex, there was an increased risk of attack during ARP compared to the previous two years (RR: 2.566, 95%CI: 1.075-6.124, P=0.034). Our preliminary study suggested that COVID-19 can trigger exacerbation of MS. © 2021
Related Docs
View other Related Docs
1. Covid-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight With No Bystander Effect?, Multiple Sclerosis and Related Disorders (2021)
2. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic, Biomolecules (2021)
3. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (8)
Masoud Etemadifar (6)
Other Related Docs
4. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
5. Impact of the Covid-19 Pandemic on the Psychological Status and Cortisol Level of Multiple Sclerosis Patients, Neuropsychological Rehabilitation (2023)
6. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)
7. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
8. Early Predictors of Conversion to Secondary Progressive Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2021)
9. Prevalence and Risk Factors of Dysphagia in Patients With Multiple Sclerosis, Dysphagia (2022)
10. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
11. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
12. Self-Reported Safety of the Bbibp-Corv (Sinopharm) Covid-19 Vaccine Among Iranian People With Multiple Sclerosis, Human Vaccines and Immunotherapeutics (2022)
13. Does Covid-19 Increase the Long-Term Relapsing-Remitting Multiple Sclerosis Clinical Activity? a Cohort Study, BMC Neurology (2022)
14. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
15. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
16. Fear and Anxiety in Patients With Multiple Sclerosis During Covid-19 Pandemic; Report of an Iranian Population, Multiple Sclerosis and Related Disorders (2021)
17. Cns Demyelinating Disease Following Inactivated or Viral Vector Sars-Cov-2 Vaccines: A Case Series, Vaccine (2023)
18. Lateonset Multiple Sclerosis in Isfahan, Iran, Archives of Iranian Medicine (2012)
19. Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy, European Neurology (2012)
20. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)